About Lennox-Gastaut Syndrome
Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy defined by a triad of multiple seizure types (particularly tonic and atonic drop attacks), characteristic EEG pattern (slow spike-wave and fast rhythms during sleep), and intellectual disability. It typically emerges between ages 1-8 years and is frequently refractory to antiseizure medications. Cannabidiol (Epidiolex), clobazam, rufinamide, and felbamate have specific approval for LGS.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Lennox-Gastaut Syndrome trials.
EEG-confirmed LGS criteria (slow spike-wave <3Hz, tonic seizures, cognitive impairment) must be documented at baseline
Drop attack (tonic and atonic seizure) frequency diary over minimum 3 months is required for most LGS trials
Etiology (structural, genetic, unknown) should be documented — some trials exclude specific etiologies
Prior and current antiseizure medication history (at least 2 failed medications) is typically required to confirm refractory status
Patient Resources
Find recruiting Lennox-Gastaut Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Lennox-Gastaut Syndrome. Updated daily.